Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective

Poly (ADP-ribose) polymerase inhibitors (PARPis) have demonstrated clinical activity in patients with BRCA1 and/or BRCA2 mutated breast, ovarian, prostate, and pancreatic cancers. Notably, BRCA mutations are associated with defects in the homologous recombination repair (HRR) pathway. This homologou...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2023-01, Vol.179, p.136-146
Hauptverfasser:	Herzog, Thomas J., Vergote, Ignace, Gomella, Leonard G., Milenkova, Tsveta, French, Tim, Tonikian, Raffi, Poehlein, Christian, Hussain, Maha
Format:	Artikel
Sprache:	eng
Schlagworte:	Breast neoplasms Female Genomic Instability Homologous Recombination Humans Metastatic pancreatic neoplasms Ovarian neoplasms Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Poly(ADP-ribose) polymerase inhibitors Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Prostate neoplasms Recombinational DNA Repair Ribose - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!